AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03532152 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pure Purr VR technology
Description: The Pure Purr technology consists of BoboVR X1 headset with pre-installed software. The virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen. Also, the headset is able to play audio and transmit it via the headphones.~The audio sequence has been modified by adding a binaural effect and has been synchronized with the tact of respiratory movements and the frequency of heart rate.
Study NCT03532152 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VR technology
Description: The sham technology includes an identical BoboVR X1 virtual reality headset with pre-installed software. The audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.
Study NCT04551950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered intravenously as per standard of care.
Study NCT04551950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was administrated as indicated for standard of care.
Study NCT04551950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin was administered intravenously as per standard of care.
Study NCT04551950 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Participants received radiotherapy as per standard of care.
Study NCT01802190 — intervention group
Intervention type: GENETIC
Intervention: Deafness patients
Description: SLC17A8 et POU4F3 mutations genes analysis on blood samples of deafness patients.
Study NCT02106520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT02106520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02657447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betalutin with lilotomab dose 1
Description: 15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1
Study NCT02657447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betalutin with lilotomab dose 2
Description: 15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2
Study NCT01928186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FLT PET
Study NCT04161261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: To measure the facial nerve stimulation threshold for one mid-array and one apical electrode of the implant using the pulse-train stimuli
Study NCT01928186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01928186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Run-in (short pre-surgery course) of endocrine-targeted therapy
Description: Patients undergo run-in (short pre-surgery course) of endocrine-targeted therapy with aromatase inhibitor between the two (baseline and repeat) FLT PET scans. This is not an experimental therapy. This is a standard of care therapy that patients will continue after surgery, when the study is completed.
Study NCT04077112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Child Interaction Therapy
Description: Behavioral parent training program targeting parent-child relationship
Study NCT04077112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Child Interaction Therapy
Description: Behavioral parent training program targeting parent-child relationship
Study NCT03879811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: Oral TMZ at 150mg/m2
Study NCT03879811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1
Study NCT00066027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg doxycycline hyclate
Description: Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years
Study NCT00066027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the placebo group took a placebo look-alike twice daily for two years.
Study NCT02296255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix®, GlaxoSmithKline
Description: 3 doses (0,1,6 months) of Cervarix®, GlaxoSmithKline
Study NCT02396589 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Group
Description: Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
Study NCT02396589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Modifications Group
Description: The standardized components include assessment, identification of five problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of a solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
Study NCT05848427 — intervention group
Intervention type: OTHER
Intervention: LUSZ P
Description: LUSZ protocol applied to WOSS in-hospitalized Covid-19 patients: a Corticosteroid Therapy-enhanced Standard Care (CTSC), a standard care enhanced by corticosteroid (methylprednisolone) treatment.
Study NCT00407303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate
Description: 30 mg, 45 mg
Study NCT00407303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.0mg/m2, 1.3 mg/m2
Study NCT04117282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gait training
Description: training for improving the quality of gait through adjusting gait cycle phases time and improving the functional level and independence during gait
Study NCT04117282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gait training
Description: training for improving the quality of gait through adjusting gait cycle phases time and improving the functional level and independence during gait
Study NCT00808665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will be given 0.7 mcg/kg/hr of dexmedetomidine over the first hour of surgery, followed by continuous infusion of 0.5 mcg/kg/hr of dexmedetomidine for the next 2 hours of surgery. Dexmedetomidine dose will be reduced to 0.2 mcg/kg/hr for the duration of the procedure and continued at that rate for four hours postoperatively. Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
Study NCT00808665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
Study NCT00715780 — intervention group
Intervention type: DRUG
Intervention: soluble human insulin
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00715780 — intervention group
Intervention type: DRUG
Intervention: biphasic human insulin
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00715780 — intervention group
Intervention type: DRUG
Intervention: insulin NPH
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00662116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alagebrium
Description: 200 mg (two 100 mg tablets) two times daily for 24 weeks
Study NCT00662116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets - two tablets taken twice daily
Study NCT01991119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propafenone
Study NCT01991119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronedarone
Study NCT00715780 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00715780 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00715780 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT02138929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.
Study NCT03579810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational
Description: The educational intervention helped to increase the knowledge of attitudes, and habits of healthy lifestyle in children, parents and teachers and it was based on health promotion models and social cognitive theory, to be articulated with the Institutional Educational Project through the pedagogical component that integrates three areas, physical activity, healthy eating, and the knowledge of the body and the heart with the dynamics of the educative community.~The program covered self-care of the body and heart, healthy diet, and physical activity
Study NCT03579810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group did not receive an educational intervention in areas of physical activity, healthy eating, and the knowledge of the body and the heart. Instead, children received the standard curriculum in health and physical activity of the national Ministry of Education.
Study NCT03367143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT03367143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study NCT03367143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT03367143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02983864 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BASICS
Description: A one session intervention focused on reducing drinking with motivational interviewing
Study NCT02983864 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated BASICS
Description: A one session intervention focused on reducing drinking and sexual behavior while drinking
Study NCT02983864 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: A one session intervention focused on increasing relaxation skills
Study NCT02983864 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Bystander
Description: A one session intervention focused on reducing sexual assault with a focus on the role of alcohol
Study NCT02138929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE 225
Description: Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.~Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase.
Study NCT04586608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MCT/ω-3 fatty acids
Description: The provision of ω-3 fatty acids to premature neonates in the Parenteral Nutrition.
Study NCT04586608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: soybean oil-based IVFE
Description: soybean oil-based IVFE
Study NCT03342209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy
Description: A high flow nasal cannula will be implemented to the CO-poisoned patients. In the meantime, intravenous access and cardiac monitorization will have been establishing. When the high flow nasal cannula becomes ready, the first venous blood sample will be taken and the treatment will be started without any delay. The gas flow rate will be started at the rate of 30 liters per minute and will be increased to the max flow rate which patient can tolerate and FiO2 of 1.0. If the first COHb level is lesser than 10%, the patient will be excluded and will receive standard emergency care.~The blood sample will be drawn from existing IV access every 10 minutes until the COHb levels become %50 or lesser of the initial level.~Once the COHb level becomes 50% of initial measurement, following blood samples will be taken in every 30 minutes.
Study NCT03783312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
Study NCT03783312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
Study NCT03783312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen
Description: 800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
Study NCT03437980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: A bolus of 0.7 mg/kg will be given initially, additional incremental doses of 20 mg propofol will be given if the patient complained of pain or moved arms towards the back. Patients will be sitting on the middle of the operating table facing towards the table's foot. The table's foot will be dropped 45 degrees for a comfortable chair position, Monitoring through pulse oximeter (SaO2), non-invasive blood pressure (NIBP) adjusted every 2 minutes automatic measuring and capnography tube in contact with nostrils.
Study NCT04022265 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant placement
Description: Full-thickness muco-periosteal flaps will be elevated, and the alveolar bone exposed to prepare the bed for the implant installation
Study NCT04022265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implant placement
Description: Full-thickness muco-periosteal flaps will be elevated, and the alveolar bone exposed to prepare the bed for the implant installation
Study NCT02271763 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: subjects' neck will be scanned using ultrasound
Study NCT02271763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: subjects' neck will be scanned using ultrasound
Study NCT03641690 — intervention group
Intervention type: OTHER
Intervention: Empirical antimicrobial therapy
Description: All patients with pulmonary symptoms received empirical antimicrobial therapy with ceftriaxone and rovamycin or levofloxacin on admission and this was subsequently adapted to any documented bacterial infection if positive.
Study NCT02337816 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic surgery, obtainment of biological samples
Study NCT02564094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Description: Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
Study NCT03576807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD20 CAR-T cells
Description: A total of 1 - 20×10\^6 CD20 CAR-T cells/kg will be administered by IV infusions.
Study NCT01503229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given by mouth
Study NCT01503229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01503229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01503229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT04281966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ability School Engagement Program Conference
Description: The ASEP conference focuses on understanding the reasons behind why the young person is not attending school regularly, understand how the young person's non-attendance affects other conference participants, highlight the legal consequences of parents and/or guardians to ensure that their child attends school, and the development of a young person-centered Action Plan, which will specifically detail the actions that all parties are to take over the next three months to ensure that the young person re-engages with school and/or transitions into paid work.
Study NCT01632007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Study NCT01632007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin 25 mg
Study NCT01632007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02613910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration
Study NCT02613910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/paracetamol
Description: Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
Study NCT02613910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine (cetirizine or equivalent)
Description: Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration
Study NCT02613910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prednisolone
Description: Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
Study NCT04296331 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: POC
Description: DC DOC's current testing practice offers opt-out POC testing with the INSTI® finger stick test at entry
Study NCT04296331 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ag/Ab
Description: The DC DOC will transition from offering their current POC testing upon entry to offering opt-out HIV testing with Ag/Ab: ARCHITECT® laboratory-based test.
Study NCT04296331 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: POC + Ag/Ab
Description: As the DC DOC transitions to utilizing the Ag/Ab: ARCHITECT® laboratory-based test from their current POC testing, jail nurses will offer new entrants op-out testing with the two methods
Study NCT01150149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No face touch
Study NCT01150149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical face mask
Study NCT01150149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical face mask + no face touch
Study NCT04369443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Large volume Acute Normovolemic Hemodilution
Description: Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
Study NCT03776435 — intervention group
Intervention type: RADIATION
Intervention: Abdomen CT
Description: Patients are divided into CT-exposed or unexposed group according to the presence of claims codes of abdominopelvic CT conducted within seven days before and after appendectomy. The seven-day threshold is arbitrarily determined considering the delay in the diagnosis of appendicitis and the postoperative examination for surgical complication.
Study NCT00612573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 0.6 mg/kg/day
Description: doxycycline 40 mg/day, oral, 12 weeks
Study NCT00612573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 1.2 mg/kg/day
Description: doxycycline 80 mg/day, 12 weeks
Study NCT01964638 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Targeted Biopsy
Study NCT00612573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 2.4 mg/kg/day
Description: doxycycline 160 mg/day, 12 weeks
Study NCT02864160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Life style coaching in 3 in-person meetings and 14 phone calls; written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
Study NCT02788708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00612573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 12 weeks